Biocause Pharma(SZ:000627) Zheng Quan Ri Bao Wang·2025-08-09 04:23Core Viewpoint - Tianmao Industrial Group Co., Ltd. has announced its decision to voluntarily delist from the Shenzhen Stock Exchange to protect shareholder interests amid ongoing financial difficulties and regulatory scrutiny [1][2][4]. Group 1: Delisting Announcement - The company plans to withdraw its A-share listing and will apply to transfer to the National Small and Medium Enterprises Share Transfer System after delisting [1]. - A cash option will be provided to dissenting shareholders, with an exercise price of 1.60 CNY per share, representing a 10.34% premium over the last closing price of 1.45 CNY [1][5]. - The company will hold a temporary shareholders' meeting on August 25, 2025, to review the delisting proposal [1][5]. Group 2: Financial Struggles - The company has faced continuous declines in performance, with net profits dropping by 67.32%, 18.88%, 41.78%, and 337.82% from 2020 to 2023, culminating in a net loss of 6.52 billion CNY in 2023 [3]. - For the first three quarters of 2024, the company reported a net loss of 3.33 billion CNY, with forecasts indicating a potential loss of 5 to 7.5 billion CNY for the full year [3]. Group 3: Regulatory Issues - The company is on the verge of forced delisting due to failure to disclose its 2024 annual report, which was originally due on April 29, 2024 [2]. - The China Securities Regulatory Commission (CSRC) has initiated an investigation into the company for failing to timely disclose regular reports, leading to a suspension of trading since May 6, 2024 [2]. Group 4: Market Context - The number of companies voluntarily delisting has increased, with Tianmao being the third company to do so in 2023, reflecting stricter delisting regulations and increased operational pressures [7]. - The new regulations aim to reduce "shell" companies and enhance investor protection through mechanisms like cash options for shareholders [7].